Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical ...

MapLight has become the second Massachusetts-linked biotech to go public this year. The company sold 14.75 million shares at ...

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech ...

By Arasu Kannagi Basil (Reuters) -MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company to go public under a rarely used regulatory ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Jyong Biotech Ltd., a Taiwan-based biotechnology company, recently completed its IPO on Nasdaq and participated in the BIO 2025 International Convention in Boston, where it showcased its flagship ...